25 research outputs found

    Implications of Efficient Hepatic Delivery by Tenofovir Alafenamide (GS-7340) for Hepatitis B Virus Therapy

    Full text link
    Inside the Peristyle Court of Tuthmosis III, view looking north showing two granite pillars representing Upper and Lower Egypt with a statue of Amun-Re at left; Pylon IV, preceded by obelisks, is the façade of the Ipet-sut. This comprises, from the entrance inwards: a hypostyle hall dominated by the remaining obelisk of Hatshepsut; pylons V and VI; a hall with historical reliefs (the 'Annals of Tuthmosis III'); and a granite shrine of Philip Arrhidaeus (reigned 323-316 BCE) containing a 'solar bark' (the ceremonial boat of the sun-god). The sacred shrine of the Middle Kingdom was originally situated in the 'Middle Kingdom Court' behind an earlier version of the bark shrine. Source: Grove Art Online; http://www.groveart.com/ (accessed 1/19/2008

    Dose-dependent intracellular accumulation of test ERAs in sandwich-cultured human hepatocytes.

    No full text
    <p>Ambrisentan displayed the lowest intracellular accumulation followed by bosentan, sitaxsentan, and macitentan. Data are presented as mean (±SD) micromolar (µM) concentration; n = 3 donors; *P<0.05 vs. corresponding intracellular accumulation value for ambrisentan at the same test concentration.</p

    Uptake of bosentan and macitentan into human hepatocytes.

    No full text
    <p>ERAs were evaluated either in the absence or presence of the transporter inhibitors rifampicin (40 µM) and cyclosporin A (5 µM). Data presented as mean (±SD) pmol/million cells; n = 4 donors; *P<0.05 for comparisons indicated.</p

    d<sub>8</sub>-Taurocholate (d<sub>8</sub>-TCA) total (A) and cellular (B) accumulation in sandwich-cultured human hepatocytes exposed to ambrisentan, bosentan and macitentan.

    No full text
    <p>Bosentan and macitentan treatment resulted in a dose-dependent reduction in total accumulation of d<sub>8</sub>-TCA. Ambrisentan, bosentan and macitentan treatment each resulted in a dose-dependent reduction in cellular accumulation of d<sub>8</sub>-TCA. Data presented as mean (±SD) expressed as percent of control treated; n = 3 donors; *P<0.05 bosentan vs. control; # P<0.05 macitentan vs. control.</p

    Effect of Ambrisentan, Bosentan, Sitaxsentan, and Macitentan on Hepatic Uptake and Efflux Transporters.

    No full text
    a<p>Data presented as mean ± standard deviation for 3 independent studies performed in duplicate;</p>b<p>Data presented for a single experiment preformed in duplicate;</p>c<p>Data previously reported <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0087548#pone.0087548-Ray1" target="_blank">[35]</a>. Ambrisentan, bosentan, and macitentan were tested in concentrations ranging from 0.14–100 µM.</p><p>ND = not determined.</p
    corecore